利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

274 条记录 (耗时 0.015 秒)

    BERBELINE AS IMMUNOSUPPRESANT
    13.
    发明专利
    BERBELINE AS IMMUNOSUPPRESANT 失效

    公开(公告)号：JPH07316051A

    公开(公告)日：1995-12-05

    申请号：JP10874894

    申请日：1994-05-23

    申请人： KANEGAFUCHI CHEMICAL IND

    发明人： MATSUO KAZUHIKO ,  KITAHARA MIKIRO ,  KATSUMI TOSHIAKI ,  SHIRAISHI TADAYOSHI

    IPC分类号： C07D455/03 ,  A61K31/435 ,  A61P37/06 ,  A61P37/08

    摘要： PURPOSE:To obtain a new immunosuppressant, containing an immunosuppressively effective amount of berbeline (salt), capable of suppressing the production of an antibody without inhibiting proliferating reactions of lymphocytes and hardly causing side effects. CONSTITUTION:This immunosuppressant contains berbeline (salt) expressed by the formula alone or in a mixture with an excipient or a carrier and is administered as an oral agent or a parenteral agent. The daily dose of the immunosuppressant is preferably 0.1-500mg expressed in terms of the amount of the berbeline (salt) in the case of parenteral administration and 30mg to 3g in the case of oral administration. The oral agent is produced by using, e.g. starch, lactose, white sugar, mannitol, CMC, corn starch and an inorganic salt and distilled water for injection, a physiological saline, an aqueous solution of glucose, a vegetable oil for injection and sesame oil, etc., can be used as a diluent for the parenteral agent.

    14.
    发明专利
    失效

    公开(公告)号：JPH0469632B2

    公开(公告)日：1992-11-06

    申请号：JP25242584

    申请日：1984-11-29

    申请人： SS PHARMACEUTICAL CO

    发明人： IKEGAWA TETSUO ,  SHIMADA FUMITAKE ,  CHO SOTETSU ,  UEBABA KAZUO

    IPC分类号： A61K31/47 ,  A61P1/12 ,  C07D455/03

    摘要： A 13-propylberberine salt, which is represented by the following general formula (I):wherein X means HSO 4 or H 2 PO 4 , has strong inhibitory effect against secretion, good stability and high water solubility. Its effects are shown promptly after its oral administration.

    ANTINEPHRITIC AGENT
    16.
    发明专利
    ANTINEPHRITIC AGENT 失效

    公开(公告)号：JPH04193830A

    公开(公告)日：1992-07-13

    申请号：JP32108690

    申请日：1990-11-27

    申请人： TSUMURA & CO

    发明人： SUZUKI YOSHIO

    IPC分类号： C07D455/03 ,  A61K31/47 ,  A61K31/715 ,  A61P13/02 ,  A61P15/00 ,  C08B37/00

    摘要： PURPOSE:To provide the subject antinephritic agent containing one or more of berberine, pachyman or coptisine as the active components. CONSTITUTION:One or more selected from berberine of formula I, i.e., an alkaloid contained, e.g. in galenical drug Coptic rhizome, coptisine of formula II and pachyman (e.g. beta-pachyman of formula III), i.e., a polysaccharide contained in galenical drug hoelen, etc., and having a structure composed of many glucoses bonded through 1 3 bond are used as the active components. The above- mentioned agent can be administrated in any dosage form as an oral preparation and a parenteral preparation. In order to exhibit the prescribed effect, a daily oral dose of 30mg to 3g is used suitably divided in several times or 0.1-500mg/ day is parenterally administrated in a dosage form of intravenous injection, intravenous drip infusion, subcutaneous injection or intramuscular injection.

    17.
    发明专利
    失效

    公开(公告)号：JPH04501122A

    公开(公告)日：1992-02-27

    申请号：JP51130490

    申请日：1990-07-19

    IPC分类号： A61K8/00 ,  A61K8/30 ,  A61K8/49 ,  A61K31/23 ,  A61Q19/00 ,  C07C20060101 ,  C07C69/608 ,  C07C69/96 ,  C07C219/34 ,  C07C233/25 ,  C07C235/46 ,  C07C235/60 ,  C07C255/55 ,  C07C271/28 ,  C07C271/44 ,  C07C403/20 ,  C07C403/22 ,  C07D277/66 ,  C07D417/04 ,  C07D455/03 ,  C07D455/04 ,  C07F15/02

    摘要： The effects of acne and psoriasis are relived by applying either topically or by oral adminstration, a compound having the structure: wherein R1, R2, R3, R4 and R5 are independently selected from the group consisting of H, Cl, straight or branched alkyl of 1 to 10 carbon atoms, NO2, COOR6, CN, OR6, NR6R7, NR6C(=S)NR7R8, NF6COR7, SO2NR6R7, CH(CH3)COOH, CONR6R7, COR6, OCONR6R7, NR6COONR7, R9OR6, NR6SO2R7, Si(CH3)3, and NR6CONR7R8, R3 together with R4 forms a benzo ring or taken together with R2 forms a benzo or tetrahydrobenzo ring or together with R2 and R1 forms a: moiety or together with R2 forms a moiety or R2 together with R1 forms a benzo ring or R2 together with R3 forms a moiety, or R1 is independently selected from the group consisting of moiety, R6, R7 and R8 are indenpendently selected from the group consisting of straight or branched alkyl containing from 1 to 10 carbon atoms, aryl and containing from 6 to 10 carbon atoms and hydrogen, and R9 is alkylene or 1 to 6 carbon atoms, and iron carbonyl complexes thereof, to an area of the human skin in an amount effective to repair damage due to acne or psoriasis. This treatment is not accompanied by substantial discomfort or dermatological irritation.

    LIVER DISORDER IMPROVER
    19.
    发明专利
    LIVER DISORDER IMPROVER 失效

    公开(公告)号：JPH0269416A

    公开(公告)日：1990-03-08

    申请号：JP22034788

    申请日：1988-09-05

    申请人： TSUMURA & CO ,  KITASATO INST

    发明人： TANAKA MORIHISA ,  OTSUKA TAKAO ,  CHIYOU SOUTETSU

    IPC分类号： C07D491/056 ,  A61K31/435 ,  A61K31/535 ,  A61K36/18 ,  A61K36/28 ,  A61K36/73 ,  A61P1/16 ,  C07D455/03

    摘要： PURPOSE:To obtain a liver disorder improver comprising an extract of Inulae flos, an extract of Cyananchi atrati radix or berberine as an active ingredient. CONSTITUTION:Inulae flos or Cyananchi atrati radix, Japanese Chinese crude drug is extracted with water and/or an organic solvent while warming and the solvent is distilled away under reduced pressure to give an extract of Inulae flos or Cyananchi atrati radix. The extract or berberine is properly blended with a conventional excipient, a binder, a disintegrator, a surfactant, a lubricant, a fluidity promoter, etc., and pharmaceutically manufactured by a conventional procedure to give the aimed substance. The substance can be prepared into a dosage form such as tablet, capsule, granule, fine granule, powder, injection, suppository, etc. A dose is 1-50g calculated as weight of extract of Inulae flos or Cyananchi atrati radix or 10-300g berberine per adult daily in the case of oral agent and administered dividedly several times.